Your browser doesn't support javascript.
loading
Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.
Aguilera, Dolly G; Goldman, Steward; Fangusaro, Jason.
Afiliação
  • Aguilera DG; Department of Hematology-Oncology, Children's Health Care of Atlanta, Emory University, Atlanta, Georgia, USA.
Pediatr Blood Cancer ; 56(3): 491-4, 2011 Mar.
Article em En | MEDLINE | ID: mdl-21072819
Relapsed/refractory medulloblastoma (MB) has a poor outcome regardless of the treatment employed. Novel therapies are needed in an effort to improve survivals. We present two children with recurrent/refractory MB treated with bevacizumab and irinotecan both given every 2 weeks. One patient also received temozolamide. The first patient had stable disease and remains without progression after 30 months. The second patient had a near complete response that was sustained for 18 months. The regimen was well tolerated with minimal toxicity and provided prolonged progression-free survival in these two patients. Prospective clinical trials are needed to evaluate the effectiveness of this strategy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Terapia de Salvação / Resistencia a Medicamentos Antineoplásicos / Meduloblastoma / Recidiva Local de Neoplasia Limite: Child / Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2011 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Terapia de Salvação / Resistencia a Medicamentos Antineoplásicos / Meduloblastoma / Recidiva Local de Neoplasia Limite: Child / Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2011 Tipo de documento: Article